Showing for Sample Type: D.BSRA - EI_Fc-Engineered

7 Samples visible to you, out of a total of 7

ID Title UID Name File_PrimaryData Link_PrimaryData Checksum_PrimaryData Checksum_PrimaryType Parent Scientist SampleCreationDate Protocol Type LightEmission_Plasmid LightEmission_Reporter BacterialStrain MultiplicityOfInfection InfectedCells Cells_Vendor Cells_Catalog# NumberInfectedCells ExcitationWavelength EmissionWavelength ReadingIntervals Analyzer Analyzer_Vendor Dilution
ID Title UID Name File_PrimaryData Link_PrimaryData Checksum_PrimaryData Checksum_PrimaryType Parent Scientist SampleCreationDate Protocol Type LightEmission_Plasmid LightEmission_Reporter BacterialStrain MultiplicityOfInfection InfectedCells Cells_Vendor Cells_Catalog# NumberInfectedCells ExcitationWavelength EmissionWavelength ReadingIntervals Analyzer Analyzer_Vendor Dilution
38978 D.BSRA-240502ALT-1 D.BSRA-240502ALT-1 BSRA-Macrophage MRA_MBL-FcEngineered-EI.xlsx https://immport.org/shared/study/SDY2541 ea17dee57c0ec75bd0a7890fe1c1d0e9 MD5 BAC-240502ALT-1; TIS-240502ALT-1; AB-220920ALT-1; AB-220921ALT-1; AB-220920ALT-2; AB-220920ALT-3; AB-220920ALT-4; AB-220920ALT-5; AB-220920ALT-6; AB-220920ALT-7; AB-220920ALT-8; AB-220920ALT-9; AB-220920ALT-10; AB-220920ALT-11; AB-220920ALT-12; AB-220920ALT-13; AB-220920ALT-14; AB-220920ALT-15; AB-220920ALT-16; AB-220920ALT-17; AB-220920ALT-18; AB-220920ALT-19; AB-220920ALT-20; AB-220920ALT-21; AB-220920ALT-22; AB-220920ALT-23; AB-220920ALT-24; AB-220920ALT-25; AB-220920ALT-26; AB-220920ALT-27; AB-220920ALT-28; AB-220920ALT-29; AB-220920ALT-30; AB-220920ALT-31; AB-220920ALT-32; AB-220920ALT-33; AB-220920ALT-34; AB-220920ALT-35; AB-220920ALT-36; AB-220920ALT-37; AB-220920ALT-38; AB-220920ALT-39; AB-220920ALT-40; AB-220920ALT-41; AB-220920ALT-42; AB-220920ALT-43; AB-220920ALT-44; AB-220920ALT-45; AB-220920ALT-46; AB-220920ALT-47; AB-220920ALT-48; AB-220920ALT-49; AB-220920ALT-50; AB-220920ALT-51; AB-220920ALT-52; AB-220921ALT-2 Eddie Irvine 2018-04-15T0:0:0+0000 https://fairdomhub.org/sops/729 Macrophage Restriction Assay mCherry for constitutive expression, GFP under anhydrotetracycline inducible promoter GFP, mCherry H37Rv Mtb Live/dead Reporter 1.0x10^6 bacteria per mL of blood Human monocyte-derived macrophages (MDMs) N/A N/A N/A N/A N/A Fixed and analyzed 3 days post-infection, with additional 16hr post-anhydrotetracycline addition Columbus Image Data Storage and Analysis System Revvity Anhydrotetracycline added at 200 ng/mL to induce GFP expression; monoclonal antibody at 50μg/mL in R10 media without phenol
38979 D.BSRA-240502ALT-2 D.BSRA-240502ALT-2 BSRA-WBA-1 WBA_180801-BSRA-FcEngineered-EI.xlsx https://immport.org/shared/study/SDY2541 7ec236e5c5759de59b3d158cba4acf1f MD5 BAC-240502ALT-3; TIS-240502ALT-1; AB-220920ALT-1; AB-220921ALT-1; AB-220920ALT-2; AB-220920ALT-3; AB-220920ALT-4; AB-220920ALT-5; AB-220920ALT-6; AB-220920ALT-7; AB-220920ALT-8; AB-220920ALT-9; AB-220920ALT-10; AB-220920ALT-11; AB-220920ALT-12; AB-220920ALT-13; AB-220920ALT-14; AB-220920ALT-15; AB-220920ALT-16; AB-220920ALT-17; AB-220920ALT-18; AB-220920ALT-19; AB-220920ALT-20; AB-220920ALT-21; AB-220920ALT-22; AB-220920ALT-23; AB-220920ALT-24; AB-220920ALT-25; AB-220920ALT-26; AB-220920ALT-27; AB-220920ALT-28; AB-220920ALT-29; AB-220920ALT-30; AB-220920ALT-31; AB-220920ALT-32; AB-220920ALT-33; AB-220920ALT-34; AB-220920ALT-35; AB-220920ALT-36; AB-220920ALT-37; AB-220920ALT-38; AB-220920ALT-39; AB-220920ALT-40; AB-220920ALT-41; AB-220920ALT-42; AB-220920ALT-43; AB-220920ALT-44; AB-220920ALT-45; AB-220920ALT-46; AB-220920ALT-47; AB-220920ALT-48; AB-220920ALT-49; AB-220920ALT-50; AB-220920ALT-51; AB-220920ALT-52; AB-220921ALT-2 Eddie Irvine 2018-08-01T0:0:0+0000 https://fairdomhub.org/sops/729 Whole Blood Restriction Assay https://www.addgene.org/26161/ Photorhabdus luminescens H37Rv Mtb-Lux 1.0x10^6 bacteria per mL of blood Human whole blood cells N/A N/A N/A N/A N/A Immediately after infection, then every 24 hours up to 120 hours Tecan Spark 10M Tecan Antibody treatments at 25ug/mL in 300µL total volume; Rifampin at 0.25ug/mL
38980 D.BSRA-240502ALT-3 D.BSRA-240502ALT-3 BSRA-WBA-2 WBA_180919-BSRA-FcEngineered-EI.xlsx https://immport.org/shared/study/SDY2541 fc1fb6a448d4081b51af26b2b612b0e4 MD5 BAC-240502ALT-3; TIS-240502ALT-1; AB-220920ALT-1; AB-220921ALT-1; AB-220920ALT-2; AB-220920ALT-3; AB-220920ALT-4; AB-220920ALT-5; AB-220920ALT-6; AB-220920ALT-7; AB-220920ALT-8; AB-220920ALT-9; AB-220920ALT-10; AB-220920ALT-11; AB-220920ALT-12; AB-220920ALT-13; AB-220920ALT-14; AB-220920ALT-15; AB-220920ALT-16; AB-220920ALT-17; AB-220920ALT-18; AB-220920ALT-19; AB-220920ALT-20; AB-220920ALT-21; AB-220920ALT-22; AB-220920ALT-23; AB-220920ALT-24; AB-220920ALT-25; AB-220920ALT-26; AB-220920ALT-27; AB-220920ALT-28; AB-220920ALT-29; AB-220920ALT-30; AB-220920ALT-31; AB-220920ALT-32; AB-220920ALT-33; AB-220920ALT-34; AB-220920ALT-35; AB-220920ALT-36; AB-220920ALT-37; AB-220920ALT-38; AB-220920ALT-39; AB-220920ALT-40; AB-220920ALT-41; AB-220920ALT-42; AB-220920ALT-43; AB-220920ALT-44; AB-220920ALT-45; AB-220920ALT-46; AB-220920ALT-47; AB-220920ALT-48; AB-220920ALT-49; AB-220920ALT-50; AB-220920ALT-51; AB-220920ALT-52; AB-220921ALT-2 Eddie Irvine 2018-09-19T0:0:0+0000 https://fairdomhub.org/sops/729 Whole Blood Restriction Assay https://www.addgene.org/26161/ Photorhabdus luminescens H37Rv Mtb-Lux 1.0x10^6 bacteria per mL of blood Human whole blood cells N/A N/A N/A N/A N/A Immediately after infection, then every 24 hours up to 120 hours Tecan Spark 10M Tecan Antibody treatments at 25ug/mL in 300µL total volume; Rifampin at 0.25ug/mL
38981 D.BSRA-240502ALT-4 D.BSRA-240502ALT-4 BSRA-Monocyte-Depletion Monocyte_Depletion-BSRA-FcEngineered-EI.xlsx https://immport.org/shared/study/SDY2541 ec3fabbf91fab5fd1f62c4a295bd3aec MD5 BAC-240502ALT-3; TIS-240502ALT-1; AB-220920ALT-1; AB-220921ALT-1; AB-220920ALT-2; AB-220920ALT-3; AB-220920ALT-4; AB-220920ALT-5; AB-220920ALT-6; AB-220920ALT-7; AB-220920ALT-8; AB-220920ALT-9; AB-220920ALT-10; AB-220920ALT-11; AB-220920ALT-12; AB-220920ALT-13; AB-220920ALT-14; AB-220920ALT-15; AB-220920ALT-16; AB-220920ALT-17; AB-220920ALT-18; AB-220920ALT-19; AB-220920ALT-20; AB-220920ALT-21; AB-220920ALT-22; AB-220920ALT-23; AB-220920ALT-24; AB-220920ALT-25; AB-220920ALT-26; AB-220920ALT-27; AB-220920ALT-28; AB-220920ALT-29; AB-220920ALT-30; AB-220920ALT-31; AB-220920ALT-32; AB-220920ALT-33; AB-220920ALT-34; AB-220920ALT-35; AB-220920ALT-36; AB-220920ALT-37; AB-220920ALT-38; AB-220920ALT-39; AB-220920ALT-40; AB-220920ALT-41; AB-220920ALT-42; AB-220920ALT-43; AB-220920ALT-44; AB-220920ALT-45; AB-220920ALT-46; AB-220920ALT-47; AB-220920ALT-48; AB-220920ALT-49; AB-220920ALT-50; AB-220920ALT-51; AB-220920ALT-52; AB-220921ALT-2 Eddie Irvine 2021-09-23T0:0:0+0000 https://fairdomhub.org/sops/729 Blood Immune Cell Depletion (Monocyte) before Whole Blood Restriction https://www.addgene.org/26161/ Photorhabdus luminescens H37Rv Mtb-Lux 1.0x10^6 bacteria per mL of blood Human whole blood cells N/A N/A N/A N/A N/A Immediately after infection, then every 24 hours up to 120 hours Tecan Spark 10M Tecan 100uL of microbeads per mL of blood, with microbeads buffer-exchanged into 2mM EDTA-PBS
38982 D.BSRA-240502ALT-5 D.BSRA-240502ALT-5 BSRA-Neutrophil-Depletion Neutrophil_Depletion-BSRA-FcEngineered-EI.xlsx https://immport.org/shared/study/SDY2541 0e3342ec975c1c5f4f1e004f1a7ff553 MD5 BAC-240502ALT-3; TIS-240502ALT-1; AB-220920ALT-1; AB-220921ALT-1; AB-220920ALT-2; AB-220920ALT-3; AB-220920ALT-4; AB-220920ALT-5; AB-220920ALT-6; AB-220920ALT-7; AB-220920ALT-8; AB-220920ALT-9; AB-220920ALT-10; AB-220920ALT-11; AB-220920ALT-12; AB-220920ALT-13; AB-220920ALT-14; AB-220920ALT-15; AB-220920ALT-16; AB-220920ALT-17; AB-220920ALT-18; AB-220920ALT-19; AB-220920ALT-20; AB-220920ALT-21; AB-220920ALT-22; AB-220920ALT-23; AB-220920ALT-24; AB-220920ALT-25; AB-220920ALT-26; AB-220920ALT-27; AB-220920ALT-28; AB-220920ALT-29; AB-220920ALT-30; AB-220920ALT-31; AB-220920ALT-32; AB-220920ALT-33; AB-220920ALT-34; AB-220920ALT-35; AB-220920ALT-36; AB-220920ALT-37; AB-220920ALT-38; AB-220920ALT-39; AB-220920ALT-40; AB-220920ALT-41; AB-220920ALT-42; AB-220920ALT-43; AB-220920ALT-44; AB-220920ALT-45; AB-220920ALT-46; AB-220920ALT-47; AB-220920ALT-48; AB-220920ALT-49; AB-220920ALT-50; AB-220920ALT-51; AB-220920ALT-52; AB-220921ALT-2 Eddie Irvine 2021-09-23T0:0:0+0000 https://fairdomhub.org/sops/729 Blood Immune Cell Depletion (Neutrophil) before Whole Blood Restriction https://www.addgene.org/26161/ Photorhabdus luminescens H37Rv Mtb-Lux 1.0x10^6 bacteria per mL of blood Human whole blood cells N/A N/A N/A N/A N/A Immediately after infection, then every 24 hours up to 120 hours Tecan Spark 10M Tecan 100uL of microbeads per mL of blood, with microbeads buffer-exchanged into 2mM EDTA-PBS
38983 D.BSRA-240502ALT-6 D.BSRA-240502ALT-6 BSRA-Complement-Inhibition 231016_Complement_Inhibition-BSRA-FcEngineered-EI.xlsx https://immport.org/shared/study/SDY2541 44e66cde81ec19bfb8b4c805b811c8ed MD5 BAC-240502ALT-3; TIS-240502ALT-1; AB-220920ALT-1; AB-220921ALT-1; AB-220920ALT-2; AB-220920ALT-3; AB-220920ALT-4; AB-220920ALT-5; AB-220920ALT-6; AB-220920ALT-7; AB-220920ALT-8; AB-220920ALT-9; AB-220920ALT-10; AB-220920ALT-11; AB-220920ALT-12; AB-220920ALT-13; AB-220920ALT-14; AB-220920ALT-15; AB-220920ALT-16; AB-220920ALT-17; AB-220920ALT-18; AB-220920ALT-19; AB-220920ALT-20; AB-220920ALT-21; AB-220920ALT-22; AB-220920ALT-23; AB-220920ALT-24; AB-220920ALT-25; AB-220920ALT-26; AB-220920ALT-27; AB-220920ALT-28; AB-220920ALT-29; AB-220920ALT-30; AB-220920ALT-31; AB-220920ALT-32; AB-220920ALT-33; AB-220920ALT-34; AB-220920ALT-35; AB-220920ALT-36; AB-220920ALT-37; AB-220920ALT-38; AB-220920ALT-39; AB-220920ALT-40; AB-220920ALT-41; AB-220920ALT-42; AB-220920ALT-43; AB-220920ALT-44; AB-220920ALT-45; AB-220920ALT-46; AB-220920ALT-47; AB-220920ALT-48; AB-220920ALT-49; AB-220920ALT-50; AB-220920ALT-51; AB-220920ALT-52; AB-220921ALT-2 Eddie Irvine 2023-10-16T0:0:0+0000 https://fairdomhub.org/sops/729 Complement Inhibition before Whole Blood Restriction https://www.addgene.org/26161/ Photorhabdus luminescens H37Rv Mtb-Lux 1.0x10^6 bacteria per mL of blood Human whole blood cells N/A N/A N/A N/A N/A Immediately after infection, then every 24 hours up to 120 hours Tecan Spark 10M Tecan Cobra venom factor at 50ug/mL
38984 D.BSRA-240502ALT-7 D.BSRA-240502ALT-7 BSRA-Cytokine-Blockade 231016_Cytokine_Blockade-BSRA-FcEngineered-EI.xlsx https://immport.org/shared/study/SDY2542 05144ee484c2f320a5082077a54c9b7b MD5 BAC-240502ALT-3; TIS-240502ALT-1; AB-220920ALT-1; AB-220921ALT-1; AB-220920ALT-2; AB-220920ALT-3; AB-220920ALT-4; AB-220920ALT-5; AB-220920ALT-6; AB-220920ALT-7; AB-220920ALT-8; AB-220920ALT-9; AB-220920ALT-10; AB-220920ALT-11; AB-220920ALT-12; AB-220920ALT-13; AB-220920ALT-14; AB-220920ALT-15; AB-220920ALT-16; AB-220920ALT-17; AB-220920ALT-18; AB-220920ALT-19; AB-220920ALT-20; AB-220920ALT-21; AB-220920ALT-22; AB-220920ALT-23; AB-220920ALT-24; AB-220920ALT-25; AB-220920ALT-26; AB-220920ALT-27; AB-220920ALT-28; AB-220920ALT-29; AB-220920ALT-30; AB-220920ALT-31; AB-220920ALT-32; AB-220920ALT-33; AB-220920ALT-34; AB-220920ALT-35; AB-220920ALT-36; AB-220920ALT-37; AB-220920ALT-38; AB-220920ALT-39; AB-220920ALT-40; AB-220920ALT-41; AB-220920ALT-42; AB-220920ALT-43; AB-220920ALT-44; AB-220920ALT-45; AB-220920ALT-46; AB-220920ALT-47; AB-220920ALT-48; AB-220920ALT-49; AB-220920ALT-50; AB-220920ALT-51; AB-220920ALT-52; AB-220921ALT-2 Eddie Irvine 2023-09-26T0:0:0+0000 https://fairdomhub.org/sops/729 Blood Cytokine Blockade before Whole Blood Restriction https://www.addgene.org/26161/ Photorhabdus luminescens H37Rv Mtb-Lux 1.0x10^6 bacteria per mL of blood Human whole blood cells N/A N/A N/A N/A N/A Immediately after infection, then every 24 hours up to 120 hours Tecan Spark 10M Tecan Anti-IL-1B and Anti-IFNy at 1ug/mL
Powered by
 (v.1.16.0-pre)
About FAIRDOMHub | Funding and Programmes | Credits | Terms & Conditions | Imprint | Cookie preferences
Copyright © 2008 - 2024 The University of Manchester and HITS gGmbH